THE ECONOMIC BENEFIT OF AN INFECTIOUS APPROVAL PROGRAM
Author(s)
Kinky DE, Erush SC, Laskin MS, Gibson GA, The University of Pennsylvania Medical Center, Philadelphia, PA, USA
OBJECTIVE: A cost avoidance model was developed to determine potential cost savings (PCS) of a drug information service (DIS) that’s results from answering a drug information request. DESIGN: Patient-specific questions received by the drug information service were reviewed and evaluated. A panel determined whether or not appropriate drug therapy would have been employed if the DIS had not been consulted. Potential outcomes of drug information requests were classified using a decision-tree model. A severity rating with potential cost avoidance was then attached to each applicable request to predict PCS of the DIS. RESULTS: Seventy-seven of the 570 drug information responses in the six-week study period had assessable PCS to the institution. During the study interval, PCS were estimated to be $196, 000. Projected to one year, PCS reached #1.7 million. Of the savings noted, most were in the categories of increased monitoring and additional treatment. Annual PCS using a sensitivity analysis ranged from $423,601 to $1,922,560 per year. CONCLUSIONS: This model demonstrates that the DIS at our institution does provide substantial cost avoidance. This model may be modified to evaluate PCS in other areas of pharmacy practice.
Conference/Value in Health Info
1998-05, ISPOR 1998, Philadelphia, PA, USA
Value in Health, Vol. 1, No. 1 (May/June 1998)
Code
PIC9
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Multiple Diseases